[Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study].
We have retrospectively examined 94 evaluable patients with metastatic osteolysis from breast cancer (BC) and non-small cell lung (NSCLC) cancer, who received RT from Nov. 88 to Nov. 89.27 (15 BC and 12 NSCLC) were in treatment with Clodronate for at least 3 days from the beginning of RT; of the remaining 67 treated with RT alone, 31 had NSCLC and 36 BC. We have evaluated: increase in pain (IP) occurring on the first days of RT, percentages of complete pain relief (CPR) at the end of RT and 4-6 weeks after. A decreased occurrence of IP was observed more in NSCLC patients receiving RT + Clodronate compared to those treated with RT alone (33.3% vs 41.9%). Both at the end of RT and 4-6 weeks after, we registered a significant difference in the percentages of CPR in the RT + Clodronate group (40.7 vs 20.9 and 70.3% vs 53.7%). We believe the points of interest focused in this paper-greater precision in centering and defining the target volume, decreased occurrence of IP during the first days of RT, increase in percentage of CPR--need a prospective confirmation.
Caristi
N
N
Istituto di Clinica Oncologica e di Ricerca sui Tumori, Università degli Studi di Messina.
Russi
E G
EG
Adamo
V
V
Altavilla
G
G
d'Aquino
A
A
Delia
P
P
Di Carlo
M
M
Maisano
R
R
Romeo
F
F
Salvi
L
L
D001859:Bone Neoplasms / Q000150:complications* / Q000532:radiotherapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary*; D004002:Clodronic Acid / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D010014:Osteolysis / Q000209:etiology / Q000532:radiotherapy / Q000628:therapy*; D010146:Pain / Q000209:etiology / Q000532:radiotherapy; D059408:Pain Management; D012189:Retrospective Studies
D004002:Clodronic Acid
Clodronato più radioterapia nel trattamento delle osteolisi metastatiche da carcinoma mammario e polmonare non microcitoma. Studio retrospettivo.